Matured Hop Extract for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Matured Hop Bitter Acids, MHBA, MHE, Oxidized Hop Bitter Acids, Hop Bitter Acid Oxides, Aged Hop Extract

Motivation

Beer’s bitterness comes from resins in the flower of the hop plant. When those resins sit in storage, or are heated on purpose, they oxidize into a second family of bitter compounds — softer on the tongue and, as it turns out, biologically different from the bitter compounds that brewing itself creates. Matured hop extract is the concentrated, standardized form of that oxidized fraction, sold as capsules and added to some alcohol-free beverages.

Interest in it began with weight research in Japan, where drink makers wanted a food ingredient that could shrink abdominal fat without the harsh taste of the brewing-derived bitters. A second line of work followed from a different idea: that bitter compounds sensed in the gut can send a signal up the nerve connecting gut and brain, and that this signal might sharpen attention and steady mood.

This review examines what matured hop extract is, how it is thought to act, what the human and animal studies report about abdominal fat, thinking, and mood, what is known about its safety, and how it has been dosed and monitored.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article exists for matured hop extract, for matured hop bitter acids, or for hop bitter acids as a compound class.

Examine

Matured Hop Extract

Examine’s dedicated entry, written by Kamal Patel and last updated in August 2025, files the extract under brain health and keeps a running research feed of the individual human trials.

ConsumerLab

ConsumerLab has no article, product review, or test report covering matured hop extract. Its only hop-related coverage concerns a different, non-oxidized bitter hop flower extract discussed inside a general appetite-control article, which is not this intervention.

Systematic Reviews

No systematic reviews or meta-analyses for Matured Hop Extract were found on PubMed as of August 16, 2026.

Both sides of the trade-off are therefore unrepresented at this evidence level: there is no pooled analysis of the claimed benefits (abdominal fat, attention, mood) and none of the principal risks or of the forgone benefit of spending the same effort elsewhere.

Mechanism of Action

Matured hop extract comes from heat-treated or long-stored hop cones (Humulus lupulus). Storage oxidizes its α-acids and β-acids — the resins behind beer’s bitterness — into oxides called matured hop bitter acids (MHBA), which share a β-tricarbonyl group with brewing-derived iso-α-acids but are chemically distinct and undetectable as iso-α-acids (Taniguchi et al., 2015).

The route is a gut-to-brain reflex, not a drug-like tissue action. MHBA activates bitter taste receptors (TAS2R1, TAS2R8, TAS2R10) on hormone-secreting cells of the gut lining; calcium entry through the taste channel TRPM5 follows, and the cells release cholecystokinin (CCK — a gut hormone released after a meal) (Yamazaki et al., 2020). CCK stimulates its CCK1 receptor on vagus nerve fibres, the main line from gut to brainstem. Two branches follow in rodents: sympathetic (fight-or-flight) traffic to brown adipose tissue — heat-producing fat — raising uncoupling protein 1 (Yamazaki et al., 2019); and noradrenaline, an alertness signal, released into the hippocampus, the brain’s memory hub (Ayabe et al., 2018).

Pharmacologically it acts at the gut surface, not systemically: selectivity is confined to those three receptors, distribution beyond the gut wall is uncharacterised, and no human pharmacokinetic study exists — related hop bitter acids clear with a half-life near 30 minutes (Rodda et al., 2014). Absorbed material is cleared by liver oxidation and conjugation. The competing explanation, direct absorption acting on liver lipid handling as proposed for iso-α-acids, is weakened by their absence here and by cutting the vagus nerve abolishing both effects in animals.

Historical Context & Evolution

Hops entered brewing as a preservative and flavouring more than a thousand years ago, and hop cones have a separate folk-medicine history as a sedative and sleep aid in European herbalism. Within brewing, the oxidation products of stored hops were regarded for a century as a defect: bitterness that had gone “stale” and lost its clean character. That judgement was about taste, not biology, and no one had described the oxidized compounds in detail.

The pivot came from beverage research. Iso-α-acids, the bitter compounds created when hops are boiled, had been shown to lower body fat, but the daily amount required tasted too sharp to sell as a food. That commercial obstacle sent the Kirin laboratories to the oxidized fraction, whose bitterness is softer. The chemistry was resolved first: the autoxidation products of humulone were isolated and named (Taniguchi et al., 2014), and a preparation and assay method for the whole fraction followed.

Findings then arrived in two waves. First metabolic: heat production in brown fat in rodents, then a 200-person trial of abdominal fat, which supported a Japanese functional-food claim and a commercial alcohol-free beer. Second neurological, from 2018 onward: memory through the vagus nerve, inflammation-driven memory loss, and human attention and mood trials. Nothing in this record has been overturned; what has changed is that the target organ shifted from fat tissue to the gut-brain axis, and the evidence remains single-sponsor.

Expected Benefits

High 🟩 🟩 🟩

No effect reaches this level. There is no meta-analysis, no trial conducted by a group independent of the manufacturer, and no replication of any endpoint outside the sponsor’s own programme.

Medium 🟩 🟩

Reduction in Abdominal Visceral Fat

In healthy overweight adults, twelve weeks of a beverage standardized to 35 mg of MHBA lowered visceral fat area on abdominal imaging against placebo at weeks 8 and 12, with total abdominal fat lower at week 12. The proposed route is greater energy expenditure rather than reduced eating: recorded food intake and step counts did not separate the groups. Evidence is one 200-participant randomized trial plus an exploratory re-analysis, both designed, funded, and analysed by the manufacturer, Kirin (Morimoto-Kobayashi et al., 2016; Suzuki et al., 2018).

Magnitude: Small: at twelve weeks body-fat ratio changed by −0.10% on the extract versus +0.41% on placebo, body weight by −0.47 kg versus −0.02 kg, and waist by −0.97 cm versus −0.58 cm; the visceral fat difference itself is reported graphically rather than as a number.

Attention and Executive Function ⚠️ Conflicted

Two twelve-week randomized trials in adults aged 45–69 who perceived their own cognitive decline reported better divided attention and interference control on the extract, and a single-dose crossover trial found the same direction acutely — summarized by the American Botanical Council, which identifies Kirin as its funder. Memory measures moved only inside a subgroup. The key limitation is stated by the investigators themselves: when the separate measures were combined into one score corrected for multiple testing, the group difference disappeared (Fukuda et al., 2020a; Fukuda et al., 2020b).

Magnitude: Direction is positive and confined to attention and processing-speed measures (verbal fluency at week 6, interference test at week 12, symbol-digit substitution at week 12, each reported as statistically significant — a difference large enough to be unlikely to arise by chance); the published abstracts and discussions give significance levels without a between-group effect size (a number expressing how large the difference between the groups was) for these scores.

Low 🟩

Mood State, Anxiety, and Mental Fatigue

Self-rated fatigue and anxiety improved against placebo over twelve weeks (Fukuda et al., 2020a), and a salivary stress marker released under mental load fell in a second trial (Fukuda et al., 2020b). An uncontrolled three-week study of an alcohol-free beer reported better overall mood (Fukuda et al., 2022).

Magnitude: Directionally positive on questionnaire scales at twelve weeks, with fatigue and anxiety differences reported as statistically significant; the trials publish significance levels without a score change or effect size for these scales.

Acute Rise in Vagal (Parasympathetic) Tone

A single 35 mg dose raised high-frequency heart rate variability (HRV — beat-to-beat variation tracking vagus nerve control of the heart) against placebo in a 34-person crossover trial (Kanatome et al., 2023). It is the only direct human test of the gut-brain route mapped in animals (Ano et al., 2020).

Magnitude: Acute and modest: within one test session high-frequency power rose by 322.2 ms² and total power by 630.6 ms² against placebo (95% confidence intervals — the ranges within which the true effect most likely falls — 28.0–616.4 and 87.0–1174.2), while heart rate and the low-to-high frequency ratio did not change.

Speculative 🟨

Protection Against Inflammation-Driven Cognitive Decline

In mice, the extract calmed the brain’s immune cells and preserved memory after inflammatory challenge and in an Alzheimer’s model (Ano et al., 2020). The basis is animal and mechanistic only; no human endpoint exists.

Sleep Quality and Daytime Work Performance

A three-week single-arm study of an alcohol-free beer containing the extract reported better sleep quality and work performance (Fukuda et al., 2022). With no control group or blinding, expectation cannot be separated from ingredient.

Benefit-Modifying Factors

Baseline abdominal fat: The fat findings come from adults with a body mass index (BMI — weight relative to height) of 25 to under 30 who were not dieting. Lean individuals and those already in an energy deficit are untested.
Baseline cognitive status: Attention gains were largest in participants who perceived decline but had not sought medical help. No benefit is shown in diagnosed mild cognitive impairment (thinking problems short of dementia) or in unimpaired younger adults.
Vagal nerve integrity: The entire mechanism runs through vagus nerve signalling; in animals, cutting that nerve abolishes both the fat and the memory effects. Conditions that damage autonomic nerves, such as long-standing diabetes, would plausibly blunt the response.
Physical activity: In the manufacturer’s re-analysis, visceral fat reduction correlated with daily step count, and the interaction between extract and walking approached significance, suggesting light activity and the extract work better together than either alone (Suzuki et al., 2018).
Bitter receptor genotype: The effect starts at TAS2R1, TAS2R8, and TAS2R10 — receptors that sense bitter compounds. Common variants in bitter receptor genes alter sensitivity to other bitter compounds, so a genetic modifier is plausible but has not been tested for this extract.
Sex: Both sexes were enrolled in balanced numbers in every trial, and no sex-stratified benefit analysis has been published, so any sex difference in response is currently unknown rather than absent.
Age: Human data span ages 20 to 69, with cognitive work concentrated at 45–69. Adults past 70 — the group with the most cognitive and metabolic room to gain — have not been studied at all.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No adverse effect of the extract itself reaches this level. Across the trials, adverse events occurred at the same rate on active and placebo, all were judged mild and unrelated, and blood, urine, liver, and kidney measures stayed inside reference ranges.

Medium 🟥 🟥

Alcohol Exposure When Beer Is Used as the Source

The compound occurs naturally in beer, which makes drinking beer for it the most likely real-world route — and the most harmful. Ordinary beer is not standardized for content, so reaching the studied 35 mg would mean substantial alcohol intake. The evidence against that trade is stronger than the evidence for the ingredient: a meta-analysis of 107 cohorts found no mortality benefit at low intake and rising risk above it, starting lower in women (Zhao et al., 2023).

Magnitude: Relative risk of death from any cause (the death rate divided by the death rate in the comparison group, so 1.19 means 19% higher) was 1.19 at 45–64 g of ethanol per day and 1.35 at 65 g or more, versus lifetime non-drinkers, and 1.22 for female drinkers overall; roughly 3–5 standard drinks per day sits in the first of those bands.

Low 🟥

Chromosomal Damage Signal in Cell Culture

The manufacturer’s own safety package reported chromosome breakage in cultured cells at high concentrations without metabolic activation. Bacterial mutation and live-animal micronucleus tests were both negative, the usual pattern for a cell-culture-only signal, and 90-day feeding produced no findings (Suzuki et al., 2018).

Magnitude: The positive result occurred at 3,330 and 5,000 µg/mL in culture; the no-observed-adverse-effect level in the 90-day rat study was above 3,484 mg/kg body weight per day in males and 4,022 mg/kg in females, thousands of times the 35 mg human daily intake.

Hop Allergy and Cross-Reactivity

Hops are an established if uncommon allergen: occupational sensitization is documented, including to a plant protein that cross-reacts with fruit and nut proteins. Whether a purified bitter-acid extract carries enough of it to trigger reactions is untested (Bartolomé-Zavala et al., 2024).

Magnitude: Not quantified in available studies. Hop allergy is documented only through case reports and occupational series, so no prevalence figure or reaction rate exists for an ingested, purified hop extract.

Speculative 🟨

Gallbladder Contraction in Existing Gallstone Disease

The extract releases cholecystokinin, the hormone that makes the gallbladder contract. In someone with stones that contraction can cause biliary colic (pain from a blocked bile duct), a mechanistic concern with no reported case.

Cardiovascular Load From Sympathetic Activation

Driving sympathetic nerve traffic to raise heat production could in principle raise heart rate or blood pressure. The twelve-week trial found neither, leaving this theoretical.

Phytoestrogen Carryover in Non-Standardized Products

Hops contain 8-prenylnaringenin, a potent plant oestrogen sitting in the flavonoid fraction rather than the bitter acids. A product sold loosely as hop extract could carry an unquantified hormonal load.

Risk-Modifying Factors

Pre-existing gallstone disease: The hormone released by this extract contracts the gallbladder. Symptomatic or known stones convert a mechanism into a plausible trigger for pain, and no trial has enrolled such participants.
Hop or Cannabaceae allergy: Known hop sensitization, or occupational exposure in brewing or agriculture, raises the chance of a reaction. Cross-reactivity with fruit and nut lipid transfer proteins can widen the trigger list unpredictably.
Liver and kidney impairment: All trials enrolled healthy people, and blood chemistry stayed normal in them. Handling of these oxidized bitter acids in impaired organ function is simply unstudied, so risk here is unknown rather than low.
Sex: No sex difference in adverse events has been reported. Where the beer route is used, women reach the same alcohol-related risk at lower intake than men, which shifts the harm balance toward the capsule form.
Age: Nobody over 69 has been studied. Older adults taking multiple medications, with slower liver clearance and higher gallstone prevalence, carry the risk profile the trials specifically excluded.
Genetic factors: No polymorphism has been linked to adverse effects. Hop bitter acids are cleared by liver oxidation and conjugation, so variation in those enzymes is a theoretical rather than demonstrated modifier.

Key Interactions & Contraindications

Prescription drugs, in general: No interaction study exists for this extract. In the nearest human test, a hop supplement rich in flavonoids left four drug-metabolizing enzymes unchanged (van Breemen et al., 2020). Severity: caution. Consequence: theoretical shifts in drug blood levels.
Sedatives and central nervous system depressants (benzodiazepines such as diazepam, “z-drugs” such as zolpidem, opioids): Whole hop cone preparations are traditional sedatives. Severity: caution with whole-hop products; a bitter-acid extract carries little of the sedative fraction. Consequence: additive drowsiness.
Cholecystokinin receptor blockers (dexloxiglumide, loxiglumide): These block the exact receptor the extract signals through, and abolished its effects in animals. Severity: expected loss of benefit rather than harm. Mitigation: none available; the combination is pointless.
Glucagon-like peptide-1 agonists (semaglutide, liraglutide) and other gut-slowing agents: Both act on gut hormone signalling and satiety. Severity: monitor. Consequence: additive nausea, fullness, or delayed stomach emptying. Mitigation: separate introduction by several weeks to attribute symptoms correctly.
Over-the-counter medications: Sedating antihistamines (diphenhydramine, doxylamine) and combination sleep aids that already contain hops are the practical overlap. Severity: caution. Consequence: additive sedation and unintended double-dosing of hop material. Mitigation: read sleep-aid labels for hop content.
Supplements with additive thermogenic effects: Caffeine, synephrine, capsinoids, and green tea catechins all raise sympathetic drive or heat production. Severity: monitor. Consequence: palpitations, jitteriness, sleep disruption. Mitigation: add one at a time and keep caffeine away from the evening.
Other hop-derived supplements: Iso-α-acids, rho-iso-α-acids, xanthohumol, and bitter hop flower appetite extracts are separate fractions frequently mislabelled as interchangeable. Severity: caution. Consequence: unintended stacking of hop compounds with no combined safety data.
Other interventions: Vagus nerve stimulation devices and breathing protocols target the same pathway. Severity: no known harm. Consequence: overlapping rather than additive effects; no study has combined them.

Populations who should avoid Matured Hop Extract:

Anyone with known hop or Cannabaceae allergy, including occupational sensitization
Pregnant or breastfeeding women — no reproductive or developmental data exist at any dose
Children and adolescents under 20, the lower age bound of every trial
People with symptomatic gallstone disease, until the gallbladder question is settled
Anyone who would obtain it by drinking beer while carrying a contraindication to alcohol — alcohol use disorder, pancreatitis, advanced liver disease (Child-Pugh Class B or C, meaning moderate or severe cirrhosis), or a pregnancy

Risk Mitigation Strategies

Capsule or alcohol-free vehicle instead of beer: The assayed forms remove ethanol entirely — the only exposure here with strong evidence of harm — and deliver a defined 35 mg rather than an unknown amount.
Adherence to the studied 35 mg daily dose: Every human trial used this amount. Higher intakes have no efficacy or safety data in people, so escalation adds unmeasured risk without demonstrated extra benefit.
Label verification of bitter acid content: Products assayed for matured hop bitter acids by the validated chromatographic method carry a defined amount and little flavonoid fraction, avoiding the unquantified plant-oestrogen exposure of generic “hop extract”.
Deferral where gallstones are known or suspected: The mechanism contracts the gallbladder, the trigger for biliary colic. Imaging or a symptom review beforehand heads off the one mechanistically predictable acute event.
Discontinuation at the first allergic sign: Hives, lip or throat swelling, wheeze, or rash after dosing indicates hop sensitization, which can involve cross-reactive fruit and nut proteins and can escalate on repeat exposure.
Single-variable introduction rather than a stack: Adding it separately from caffeine, thermogenic blends, or gut-hormone drugs keeps palpitations, sleep disruption, or nausea attributable, and prevents unnoticed duplication of hop compounds.
Baseline liver enzymes where liver disease exists: Trials enrolled healthy adults only. A starting alanine aminotransferase value provides a comparison point in a population whose clearance of these compounds is unstudied.

Therapeutic Protocol

Standard dose: 35 mg of matured hop bitter acids once daily, the only dose ever tested in humans, defined by the Kirin research group of Ano and Fukuda; no independent clinic has published a protocol.
Capsule route: Powdered extract in capsules, used in both cognitive trials and the crossover study. Delivers the assayed dose without calories, alcohol, or taste, and is the form most available outside Japan.
Beverage route: 350 mL of an alcohol-free beer-style drink containing 35 mg, the vehicle used in the body fat trial. Neither route has been shown superior; the choice is about adherence and calories.
Duration before judging: Twelve weeks. Fat area separated from placebo at week 8, attention measures at weeks 6 to 12, and both trials ran to 12 weeks by design.
Time of day: No timing requirement was set in the trials, and the investigators state the effect appears independent of when the dose is taken. Acute attention data would favour morning dosing before demanding work.
Half-life and absorption: No human pharmacokinetic study of these oxidized acids exists. Related hop bitter acids peak within about 30 minutes and clear with a half-life near 30 minutes (Rodda et al., 2014), which suits a gut-receptor mechanism.
Single versus split dosing: Every trial used one daily dose, and the receptor-triggered signal is short-lived rather than concentration-dependent. Splitting has not been tested and has no mechanistic rationale.
With or without food: Trials did not tie intake to meals. The receptors involved sit in the intestinal lining and respond to the compound itself, so food is a tolerance and adherence question only.
Genetic polymorphisms: None validated for dosing. Bitter receptor variants (TAS2R family) and liver clearance enzymes are the plausible candidates, but no pharmacogenetic study of this extract has been run.
Sex-based dosing: The same 35 mg was used for men and women, with balanced enrolment and no sex-stratified dose finding. No basis exists for adjusting dose by sex.
Age considerations: Trials spanned ages 20 to 69, cognitive work at 45 to 69. For adults past 70 the dose is an extrapolation, so starting at the studied amount rather than above it is the conservative reading.
Baseline biomarkers guiding use: Waist circumference and an objective attention score anchor the two endpoints with human data. Without a starting value, neither effect — both small — can be distinguished from normal fluctuation.
Pre-existing conditions: Participants were healthy, overweight, or self-reporting cognitive decline. Use in diabetes, diagnosed cognitive impairment, or gastrointestinal disease is extrapolation from a population that excluded them.

Discontinuation & Cycling

Continuous rather than time-limited: Fat area, body fat ratio, and weight differences narrowed during the four-week follow-up after dosing stopped, so the effect depends on ongoing intake rather than persisting.
No withdrawal effects: None were reported in any trial after stopping, and none is expected: the mechanism is a receptor-triggered gut signal with no evidence of adaptation or receptor downregulation.
No tapering needed: With no withdrawal syndrome and no dependence signal, stopping abruptly is how every trial ended, including the four-week follow-up period.
Cycling not studied: No trial has compared continuous with intermittent use, and no tolerance has been documented within 12 weeks. Cycling therefore has neither evidence for nor against it.
Longest tested duration: Twelve weeks of dosing plus four weeks of follow-up. Anything beyond that — including whether small effects accumulate or plateau — is unmeasured.

Sourcing and Quality

Standardized bitter acid content: Products declaring matured hop bitter acids in milligrams, measured by the validated chromatographic assay, carry a defined dose. The trial extract held 18.3% bitter acids by weight, so extract weight alone says nothing.
Distinguish the hop fractions: Iso-α-acids, rho-iso-α-acids, xanthohumol, whole hop cone powder, and bitter hop flower appetite extracts are chemically different products with different evidence. Only the oxidized bitter acid fraction is this intervention.
Third-party testing: United States Pharmacopeia, NSF, or Informed Choice certification signals independent identity and contaminant testing. ConsumerLab has not tested this ingredient, so no public assay of marketed products exists.
Form: Capsules of standardized extract and alcohol-free beer-style beverages are the two forms with human data behind them. Regular beer is not a controlled source and carries ethanol.
Manufacturer safety documentation: The extract used in the human trials has a published genotoxicity and 90-day toxicity package. Products lacking any equivalent documentation are relying on that data without necessarily matching the material.
Country of origin and brands: Most finished products are Japanese. Kirin Holdings developed and supplies the assayed ingredient and sells it in its alcohol-free Karada Free beverage; imported or repackaged material should still state assayed bitter acid content, not just “hop extract”.

Practical Considerations

Time to effect: Attention and vagal measures shifted within a single dosing session. Body fat area separated from placebo at 8 weeks, mood and fatigue at 6 to 12 weeks, so a fair trial takes about three months.
Common pitfall — treating beer as the source: Beer contains these compounds but is not standardized for them, so the ethanol dose needed to approach 35 mg outweighs anything the ingredient offers.
Common pitfall — buying the wrong hop fraction: Products labelled hops, xanthohumol, or bitter hop appetite extract are different molecules with different evidence, and substituting one for another abandons the trial data entirely.
Common pitfall — expecting appetite suppression: The fat effect in the trial came with unchanged recorded food intake; the mechanism is energy expenditure. Expecting reduced hunger sets up a false verdict of failure.
Regulatory status: In Japan it supports a Foods with Function Claims registration. In the United States it is sold as a dietary supplement ingredient, a category the Food and Drug Administration does not review for efficacy before sale.
Cost, access, and who funds the evidence: Supply is mostly Japanese and modestly priced. No insurer or health system reimburses it, so payer incentives play no part here; the structural bias is that its developer funded every human trial.

Interaction with Foundational Habits

Sleep: Direction is neutral to mildly positive and indirect. Unlike traditional hop cone preparations, this fraction carries little of the sedative flavonoid load, so it is not a hypnotic; the only sleep data come from an uncontrolled study reporting better sleep quality. Morning dosing avoids any theoretical evening stimulation from sympathetic activation.
Nutrition: Direction is neutral. Recorded energy, protein, fat, carbohydrate, and fibre intake did not differ between groups over twelve weeks, so it neither depletes nutrients nor requires a particular diet. At 35 mg the bitterness is below taste threshold, and the alcohol-free beverage form adds modest calories worth counting.
Exercise: Direction is potentiating. In the manufacturer’s re-analysis, visceral fat loss correlated with daily step count and the interaction between extract and walking approached significance, so pairing it with light daily activity rather than using it alone matches the only supportive human data (Suzuki et al., 2018).
Stress management: Direction is blunting, on the stress-hormone axis. Salivary markers of the stress response measured after demanding mental testing were lower on the extract, and self-rated anxiety improved, consistent with the vagal pathway that also underlies slow-breathing and cold-exposure practices.

Monitoring Protocol & Defining Success

Because both demonstrated effects are small, they are detectable only against a recorded starting point. Baseline assessment therefore covers waist circumference and body composition, a resting blood pressure and heart rate, and one objective attention task rather than an impression of mental sharpness. A basic metabolic and liver panel adds value where liver, kidney, or metabolic disease already exists, since the extract has been tested only in healthy people. During use, waist and body composition are worth repeating at 4, 8, and 12 weeks — the window in which trial differences appeared — with the attention task repeated at 6 and 12 weeks. Beyond twelve weeks, six-monthly checks suffice. Trial effects faded within four weeks of stopping, which makes a deliberate off-period the cleanest test of whether a measured change belongs to the ingredient.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Waist circumference	< 80 cm women, < 90 cm men	Cheapest proxy for the visceral fat endpoint the trial measured	Measured fasted, same time of day, at the navel; conventional risk thresholds of 88 cm and 102 cm are considerably looser than these functional targets
Visceral fat area or body fat percentage	Visceral fat area < 100 cm²; body fat 21–33% women, 8–20% men	The primary and secondary endpoints of the fat trial	Computed tomography is the trial method; segmental bioimpedance is the practical substitute, done fasted and at a consistent hydration state
Body weight and body mass index	Body mass index 18.5–24.9 kg/m²	Detects the small weight change seen alongside fat loss	Weighed fasted after voiding; the trial-scale change is under 0.5 kg, so day-to-day noise exceeds the signal without a weekly average
Resting heart rate and heart rate variability	Resting heart rate 50–70 bpm; heart rate variability tracked against personal baseline	The mechanism runs through the vagus nerve, and vagal tone is what shifted acutely	No universal optimal value for heart rate variability exists; measured on waking, supine, with the same device, and compared against the individual’s own trend
Blood pressure	< 120/80 mmHg	The extract raises sympathetic nerve traffic in animals; the human trial showed no rise	Seated after five minutes’ rest, average of two readings; conventional hypertension threshold is 130/80 mmHg
Alanine aminotransferase and aspartate aminotransferase	Both < 25 U/L women, < 30 U/L men	Liver enzymes, released when liver cells are stressed; safety marker for a novel botanical	Fasting draw; conventional laboratory upper limits near 40–45 U/L are considerably looser than the functional targets
Fasting glucose and glycated haemoglobin	Glucose 75–86 mg/dL; glycated haemoglobin < 5.4%	Glycated haemoglobin reflects average blood sugar over three months; the fat trial showed no change, so a rise is a signal to look elsewhere	Twelve-hour fast; pair with fasting insulin for a more sensitive picture of metabolic change
High-sensitivity C-reactive protein	< 1.0 mg/L	General inflammation marker; the animal work centres on inflammation, but no human anti-inflammatory effect has been shown	Best deferred for two weeks after any infection or intense training block, which transiently raise it

Qualitative markers worth tracking alongside the numbers:

Sustained attention during the second half of a demanding work session
Mental fatigue in the late afternoon, rated on a simple daily scale
Anxiety and overall mood steadiness across a working week
Sleep quality and how rested mornings feel
Waistband fit, which often changes before the scale does

Emerging Research

No registered trial on ClinicalTrials.gov: Searches of the registry return no study of matured hop extract. The manufacturer registered its trials on Japan’s UMIN registry instead (body fat trial UMIN000014185), so ongoing work is difficult to track from outside Japan.
Ongoing hop-compound trials that are registered: Xanthohumol is in phase 2 testing in Crohn’s disease (NCT04590508, 20 participants, active) and in septic shock (NCT06225258, 50 participants, recruiting). Both test a different hop constituent, not the oxidized bitter acids.
Independent human work on the sibling fraction: A 2026 randomized crossover study from a European university showed a single low dose of iso-α-acids reduced inflammatory cytokine release from immune cells (Csarmann et al., 2026), evidence that non-industry groups are now testing hop bitter acids in people.
Evidence that could weaken the case: The investigators’ own combined analysis, corrected for testing many outcomes, found no group difference in the older-adult trial (Fukuda et al., 2020b). A replication using one pre-declared main outcome is the study most likely to overturn the current picture.
Bitter receptor pharmacology as the decisive mechanism test: Mapping which gut bitter receptors carry the signal (Yamazaki et al., 2020) opens the possibility of testing whether receptor variants predict response, which would either explain or undermine the small average effects.
Brain imaging of the proposed route: The trialists state that a functional MRI study (MRI — imaging that maps activity across the brain) is needed to confirm that the attention gains reflect prefrontal cortex activation through the vagal-noradrenaline pathway (Fukuda et al., 2020b). None published.

Conclusion

Matured hop extract is the oxidized bitter fraction of stored hops, taken as a capsule or in an alcohol-free drink at a single small daily dose. Its interest lies less in potency than in route: rather than acting on tissue directly, it appears to trip bitter sensors in the gut wall, release a meal hormone, and signal up the main nerve from gut to brain — a pathway that in animals both raises heat production in fat tissue and lifts alertness chemicals in memory regions.

For someone already optimizing metabolic and cognitive health, the honest reading is a small, real, but thinly replicated signal. Over three months the fat and waist changes are fractions of a kilogram and a centimetre; the attention gains show up on some tests and vanish when the results are combined and adjusted. Mood and fatigue improvements are self-reported. Safety looks reassuring at the tested dose, with no excess of side effects, normal blood work, and a wide margin in animal feeding studies, though nothing beyond three months has been measured.

The evidence base has one structural weakness that outweighs any single finding: the company that sells the ingredient designed, funded, and analysed nearly every human study, and the outlets summarizing that work are themselves supported by the botanical trade. No independent group has yet reproduced any of these results. The mechanism is unusually well mapped for a food ingredient; the measured changes in people remain small and unconfirmed.

Top - Benefits - Risks - Protocol

Matured Hop Extract for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Reduction in Abdominal Visceral Fat

Attention and Executive Function ⚠️ Conflicted

Low 🟩

Mood State, Anxiety, and Mental Fatigue

Acute Rise in Vagal (Parasympathetic) Tone

Speculative 🟨

Protection Against Inflammation-Driven Cognitive Decline

Sleep Quality and Daytime Work Performance

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Alcohol Exposure When Beer Is Used as the Source

Low 🟥

Chromosomal Damage Signal in Cell Culture

Hop Allergy and Cross-Reactivity

Speculative 🟨

Gallbladder Contraction in Existing Gallstone Disease

Cardiovascular Load From Sympathetic Activation

Phytoestrogen Carryover in Non-Standardized Products

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion